Flavia Grego's List: facts you might not know

• Shockumentaries

• Million images of Rome

• Previous versions of the Photo Tourism software matched each photo to every other photo in the set. But as the number of photos increases the number of matches explodes, increasing with the square of the number of photos. A set of 250,000 images would take at least a year for 500 computers to process, Agarwal said. A million photos would take more than a decade.

• Oncolytic Viruses: A New Weapon to Fight Cancer
   Journal of Medical Imaging and Radiation Sciences, Volume 39, Issue 3, Pages 115-127
   C. Brown, J. Bell

• Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer

• Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Researc
• The company's lead product JX-594, currently in an international Phase 2 trial for primary liver cancer, demonstrated promising Phase 1 efficacy and safety results in patients with a diverse array of common large market cancers. Jennerex's products target, attack and eradicate cancers through a novel and potent oncolytic mechanism that is dependent on highly-specific replication of the company's poxviruses in cancer cells. These products simultaneously stimulate the body's immune response to the cancer. Of note, this mechanism of action and the results in patients to date put the company's product class in a leadership position. Jennerex Biotherapeutics was established in San Francisco and in Ottawa in 2006 with Dr. David Kirn (CEO) in San Francisco and Dr. John Bell (CSO) from the Ottawa Hospital Research Institute/University of Ottawa. For more information about Jennerex and the company's robust pipeline and three clinical-stage products, please visit www.jennerex.com.

• it still killed tumor cells preferentially and was superior to chemotherapy alone
• In its phase III trial, Sunway reported a 79% response rate for H101 plus chemotherapy, compared with 40% for chemotherapy alone.
• That trial barely got off the ground before it was suspended in 2000 by Pfizer, which had just acquired Onyx's development partner, Warner-Lambert. Without funding to complete the trial on its own, Onyx discontinued the program. Kirn believes that complete phase III results would have led to U.S. Food and Drug Administration approval for Onyx-15. The virus "would have been made obsolete very quickly by much better viruses," he said, "but ... it would have been approved." Such approval, he added, would have been "huge" for the field. Instead, the field was stigmatized, since many people assumed Onyx-15 didn't work. "There's this mistaken impression out there," said Kirn. "In fact, the phase III was never done."
• adenovirus, much of the field has switched to other viruses. "Adenovirus, it turns out now in retrospect, had a number of fundamental flaws," said Kirn. "It spreads very slowly ... and the packaging capacity to express other genes is extremely limited." Also, adenovirus works poorly when given intravenously. Such systemic delivery is the field's holy grail, since injecting the virus directly into primary tumors
• Oncolytic viruses have met that challenge in preclinical studies by eliminating metastases in animals.
• Bell showed in 2003 that his viruses could eradicate advanced tumors in xenograft mouse models

4 more annotations...